Bring the immune system 
one step ahead of cancer

Off-the-shelf platform advancing next-generation in vivo immunotherapies to unlock immune response against solid tumors

THEY SUPPORT US

Redefining immuno-oncology through novel modalities

Mimicking cancer nature

A proprietary off-the-shelf platform, recapitulating both the spatial and temporal heterogeneity of the tumor, unveiling the broadest panel of cancer-associated antigens and rendering them visible to the immune system.

Scalable & cost efficient

Our platform applies precision medicine principles at large scale to improve outcomes, reduce costs, and address the needs of large patient populations facing limited therapeutic options.

Operational excellence

A team of seasoned leaders and innovators in immuno-oncology, backed by €30M in strategic funding.

Our focus: solid tumors  

Fast growing needs, insufficient solutions 

of patient face 
therapeutic failure
0 %
every year worldwide
0 M deaths

The challenge

Cancer is a moving, heterogeneous & invisible target

Colorectal cancer (CRC) is the 2nd cause of cancer mortality worldwide,

and is defined by heterogeneity, plasticity and treatment resistances

of patients have no other solution than outdated chemotherapies
0 %
of patients survive after 5-year of treatment
0 %
For these patients: the immune system, natural body’s defenser, is blinded

No immune reaction can be initiated toward tumor cells

Inefficiency 
of classical immunotherapy 

New therapeutic strategies are needed to restore anti-tumor immune response and capture cancer heterogeneity

Our solution:

Next-generation in vivo immunotherapies

From “off-the-shelf” tumor banks to first-in-class immunotherapies 

Enriched with the molecular fingerprints of tumor heterogeneity and resistances

Designed to unlock in vivo the immune system to fight back

Inspired by patients, 
driven by science

Mimicking cancer to make it visible

We model solid tumors complexity using off-the-shelf cell lines, stimulated to reveal cancer-related proteins and validated by proteogenomic and predictive model.

These cells are then tagged with an immune flare (hapten), and inactivated into ghost cells to safely educate the immune system, to target evolving cancer cells and eradicate cancer.

DNFB HAPTEN

DINITROFLUOROBENZENE

CANCER RELATED PROTEINS

From vision to execution

€30M

Invested since 2020

2

Clinical candidates advancing toward IND filing by 2027

9

Clinical sites open in 2025
Phase I/II for colorectal cancer patients in 1L
(EU & US expansion planned)

100

patients treatable per batch
thanks to our standardized & scalable platform

2 388 000

Eligible patients by 2029

Latest news and research

Linkedin

Meet Brenus at BIO-EUROPE, Vienna – 2,5 nov 2025

Linkedin

Meet Brenus at Inv€$tival Showcase, London – 17 nov 2025

Linkedin

Meet Brenus at ESMO, Berlin – 17, 21 oct 2025